Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients
Authors
Keywords
-
Journal
PROSTATE
Volume 78, Issue 5, Pages 336-342
Publisher
Wiley
Online
2018-01-27
DOI
10.1002/pros.23477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer
- (2016) Wendy Onstenk et al. CANCER TREATMENT REVIEWS
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating cell free DNA: Preanalytical considerations
- (2013) Safia El Messaoudi et al. CLINICA CHIMICA ACTA
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection
- (2012) Leander Van Neste et al. BMC Urology
- Epigenetics in Prostate Cancer: Biologic and Clinical Relevance
- (2011) Carmen Jerónimo et al. EUROPEAN UROLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer
- (2009) Jörg Ellinger et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started